Related Experiment Video
Updated: May 27, 2026
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Structure-based discovery of anti-influenza virus A compounds among medicines
Mayuko Fukuoka1, Moeko Minakuchi, Atsushi Kawaguchi
1United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1Yanagido, Gifu 501-1193, Japan.
Background:
Influenza A virus (IAV) infection is nowadays a major public health concern, in particular since the 2009 H1N1 flu pandemic. The outbreak of IAV strains resistant to currently available drugs, such as oseltamivir or zanamivir targeting the neuraminidase, is a real threat for humans as well as for animals. Thus the development of anti-IAV drugs with a novel action mechanism may be an urgent theme.
Methods:
We performed a docking simulation targeting the interface of PA interacting with PB1 using a drug database including ~4000 compounds. We then conducted cell viability assay and plaque assay using IAV/WSN/33. Finally we examined their anti-IAV mechanism by surface plasmon resonance and IAV replicon assay.
Results:
We found that benzbromarone, diclazuril, and trenbolone acetate had strong anti-IAV activities. We confirmed that benzbromarone and diclazuril bound with PA subunit, and decreased the transcriptional activity of the viral RNA polymerase.
Conclusions:
Benzbromarone and diclazuril had strong anti-IAV activities with novel action mechanism, i.e. inhibition of viral RNA polymerase.
General Significance:
Since benzbromarone and diclazuril are already used in public as medicines, these could be the candidates for alternatives in case of an outbreak of IAV which is resistant to pre-existing anti-IAV drugs.
